Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review

Most patients with advanced gastric cancer were treated with palliative therapy, which had a poor curative effect and a short survival time. In recent years, the clinical research of immune checkpoint inhibitors in advanced gastric cancer has made a breakthrough and has become an important treatment...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 934249
Main Authors Shen, Jingjing, Wang, Zhongming
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.11.2022
Subjects
chemotherapy
gastric cancer
immune checkpoint inhibitors
Oncology
radiotherapy
targeted therapy
radiotherapy
targeted therapy
immune checkpoint inhibitors
gastric cancer
chemotherapy
Online AccessGet full text

Cover

More Information
Summary:Most patients with advanced gastric cancer were treated with palliative therapy, which had a poor curative effect and a short survival time. In recent years, the clinical research of immune checkpoint inhibitors in advanced gastric cancer has made a breakthrough and has become an important treatment for advanced gastric cancer. The modes of immune checkpoint inhibitors in the treatment of advanced gastric cancer include single drug, combined chemotherapy, radiotherapy, and multiple immune drug combination therapy, among which combination therapy shows better clinical efficacy, and a large number of trials are currently exploring more effective combination therapy programs. In this paper, the new clinical research progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer is reviewed, with an emphasis on combination therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Purvish M. Parikh, Mahatma Gandhi Medical College Hospital, India; Liyuan Zhang, Second Affiliated Hospital of Soochow University, China
Edited by: Laura Ridolfi, Scientific Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.934249